The following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration whe n deciding whether a particular participant is suitable for this protocol. PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 644.1. Inclusion Criteria Participant eligibility should be reviewed and documented by an appropriate member of the investigator’s stud y team before participants are included in the study. Participants, for each assigned part, must meet all of the following inclusion criteria to be eligible for enrollment in the study : 4.1.1. Part 1 Inclusion Criteria 1.Histological or cy tological diagnosis of advanced NSCL Cor metastatic TNBC (defined as HER2 nega tive by IHC, fluorescence in situ hy bridization ( FISH) or chromogenic in situ hy bridization (CISH) and ≤10% ER/PR stain positive by IHC) with progressive disease that is resistant to standard therapy or for which no standard therap y is available or is refu sed b y the participant. 2.A mandatory archived formalinfixed paraffin embedded (FFPE) tumor tissue block (preferred) must be provided. If an FFPE tumor tissue block cannot be provided, sites should contact sponsor for approval to submit slides. For Part 1, if an archived FFPE tissue is not available, a de novo (ie, fresh) tumor sample can substitute and should be obtained in accordance with local institutional practice for tumor biopsies. 3.Females and/or male participants age 18 years. 4.Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. 5.Measurable disease as per RECI ST v. 1.1. 6.Adequate Bone Marrow Function, including: a.Absolute Neutrophil Count (ANC) 1,500/mm3or 1.5 x 109/L; b.Platelets 100,000/mm3or 100 x 109/L; c.Hemoglobin  9 g/dL. 7.Adequate Renal Function, including: a.Estimated creatinine clearance 60 mL/min as calculated using the method standard for the institution. I n unequivocal cases, a 24 hour urine can be collected and used to estimate the creatinine clea rance more accuratel y. 8.Adequate Liver Function, including: a.Total serum bilirubin  1.5 x ULN unless the participant has documented Gilbert syndrome; PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 65b.Aspartate and Alanine aminotransferase (AST and AL T) 2.5 x UL N; 5.0 x ULN if there is liver involvement b y the tumor; c.Alkaline phosphatase 2.5 x ULN ( 5 x UL N in case of bone metastasis). 9.Resolved acute effects of any prior therapy to baseline severit y or National Cancer Institute (NCI) CTCAE V5.0 Grade 1 except for adverse events (AEs) not constituting a safety risk by investigator judgment. 10. Serum or urine pregnancy test (for females of childbearing potential) negative at screening. 11.Female participants of nonchildbearing potential must meet at least 1 of the following criteria: Achieved postmenopausal sta tus, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal sta te; Have undergone a documented hy sterectomy and/or bilateral oophorectomy ; Have medically confirmed ovarian failure. All other female participants (including female participants with tubal ligations) are considered to be of childbearing potential. 12.Evidence of a personally signed and dated informed consent document indicating that the participant [or a legally acceptable representative/parent(s)/legal guardian] has been informed of all pertinent aspects of the stud y]. 13.Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures.